Cited by 419RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvanced Drug Delivery Systems

Non-viral gene delivery systems

Davis, Mark E·2002·Current Opinion in Biotechnology

Abstract

Non-viral gene delivery systems have the potential to create viable pharmaceuticals from nucleic acids. These DNA delivery systems contain lipids and/or cationic polymers. In order for these systems to be developed into commercial products, several barriers must be overcome. These include obstacles in manufacturing, formulation and stability. In vivo, problems of extracellular non-specific interactions and intracellular trafficking to the nucleus are also encountered. Recent progress has been made in overcoming these issues.

Integrity signals

Registry

Crossref · 10.1016/s0958-1669(02)00294-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Relatively low gene delivery efficiency and transgene expression have been the major barriers in non-viral vectors-based gene therapy.

    “So far, relatively low gene delivery efficiency and transgene expression have been the major barriers in non-viral vectors-based gene therapy [76, 77].”
  • Non-viral vectors face two main limitations in systemic delivery in vivo: serum stability of polyplexes after systemic administration and relatively low transfection efficiency in targeted tissues after administration.

    “There are two main limitations of non-viral vectors-mediated CRISPR/Cas9 delivery in vivo. The first one is the serum stability of polyplexes after systemic administration [73]. The second one is the relatively low transfection efficiency in the targeted tissues after administration in vivo [76, 77].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Davis, M. E.
Affiliations
California Institute of Technology (US)
Corresponding author
Davis, Mark E
Venue
Current Opinion in Biotechnology
Publisher
Elsevier BV
Published
2002-04
Volume
13
Issue
2
Pages
128-131
ISSN
0958-1669 (ISSN-L)
OpenAlex
W1969497292
Cited by
419
References
34
Citations by year
2026: 1 · 2025: 4 · 2024: 12 · 2023: 8 · 2022: 9 · 2021: 14 · 2020: 18 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 21 · 2015: 18 · 2014: 18 · 2013: 22 · 2012: 30
FWCI
1.52
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Biotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
non-viral gene delivery, nucleic acid therapeutics, cationic polymers, lipoplexes, intracellular trafficking, nuclear delivery
MeSH terms
Biological Transport, Active, Cell Nucleus, DNA, Drug Carriers, Drug Stability, Endocytosis, Genetic Vectors, Humans, Polymers, Genetic Therapy, Drug Delivery Systems, Gene Transfer Techniques, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review